Trials / Unknown
UnknownNCT04373395
Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Prospective, Single-arm, Multicenter, Exploratory Study to Evaluate the Efficacy and Safety of D-CLAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, single-arm, multicenter, exploratory study to evaluate the efficacy and safety of D-CLAG regimen in the treatment of relapsed or refractory acute myeloid leukemia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | D-CLAG | Decitabine+Cladribine+Cytarabine+Granulocyte Colony Stimulating Factor |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-12-01
- Completion
- 2023-12-01
- First posted
- 2020-05-04
- Last updated
- 2020-09-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04373395. Inclusion in this directory is not an endorsement.